In Vivo CAR-T Therapy: Pipeline, Deals, Regulatory Uncertainty, and Valuation Frameworks for 2026–2029

Executive Summary / Key Takeaways

In vivo chimeric antigen receptor T-cell (in vivo CAR-T) therapy—in which a gene-delivery vector directly reprograms circulating T cells within the patient's body—has transitioned from proof-of-concept to early clinical validation as of mid-2026. More than US$15 billion in acquisitions and partnerships have been deployed by major pharmaceutical companies since 2023, reflecting strong conviction in the modality's potential to disrupt both oncology and autoimmune disease treatment 1011. Key programs advancing in autoimmune diseases include Capstan Therapeutics' CPTX2309 (acquired by AbbVie) and Allogene's ALLO-329, while oncology programs from Eli Lilly/Kelonia (KLN-1010) and CREATE Medicines (MT-303, MT-304) are generating early clinical signals 11. Despite deal momentum, regulatory guidance from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and China National Medical Products Administration (NMPA) remains unsettled for this class, and long-term safety data are limited 1234. The 2026–2029 period will be defined by Phase 1 safety readouts, proof-of-mechanism validation, regulatory designation events, and Phase 2 efficacy data that will collectively determine whether in vivo CAR-T achieves standard-of-care status or remains a niche modality 1011.

1. Scientific and Clinical Rationale

In Vivo versus Ex Vivo CAR-T

Conventional ex vivo CAR-T—exemplified by approved therapies such as tisagenlecleucel and axicabtagene ciloleucel—requires leukapheresis (blood apheresis to harvest T cells), a four-to-six-week laboratory manufacturing phase involving genetic engineering and cell expansion, cryopreservation, and reinfusion. This process costs approximately US$300,000–$500,000 per dose, demands specialized manufacturing infrastructure, and is subject to batch variability and manufacturing failure 11.

In vivo CAR-T eliminates the ex vivo manufacturing step by administering a gene-delivery vector—most commonly a lipid nanoparticle (LNP) carrying messenger RNA (mRNA) or a lentiviral vector carrying a CAR-encoding gene—intravenously. The vector targets circulating T cells and reprograms them in situ to express tumor- or antigen-specific CARs. Projected cost-of-goods are US$10,000–$20,000 per dose, and the approach is compatible with off-the-shelf, biologic-like manufacturing capable of producing 30,000–60,000+ doses annually 11.

Key mechanistic trade-offs include the following. mRNA-based platforms (LNP-delivered) produce transient CAR expression lasting days to weeks, potentially limiting durable remission but reducing long-term safety risks such as insertional mutagenesis. Integrating lentiviral vector platforms confer more persistent CAR expression but carry heightened risk of delayed adverse events including proto-oncogene activation, for which the FDA mandates long-term follow-up (LTFU) of up to 15 years 1. In vivo CAR-T cannot be "recalled" after administration, removing a controllability option that exists with ex vivo approaches. Additionally, WestGene's prior clinical experience—the broadest in vivo CAR-T tLNP-mRNA dataset retrieved in these materials—documented robust circulating CD8+ CAR-T generation, rapid B-cell depletion, and repeat dosing up to 14 doses in a single patient with no dose-limiting toxicities (DLTs), serious adverse events, immune effector cell-associated neurotoxicity syndrome (ICANS), or infusion-related reactions, and only one Grade 1 cytokine release syndrome (CRS) event, suggesting that repeat dosing is feasible with mRNA-based platforms 10.

Why Autoimmune Diseases and Oncology?

In autoimmune indications such as systemic lupus erythematosus (SLE), myositis, systemic sclerosis, and rheumatoid arthritis, CD19-targeting CAR-T has demonstrated deep B-cell depletion and sustained drug-free remission (median approximately 15 months) in early case series, with immune "reset" occurring as naïve B cells reconstitute following B-cell aplasia 12. In vivo delivery eliminates the lymphodepletion burden and manufacturing delay, expanding potential access to a broader autoimmune patient population. In oncology, in vivo CAR-T could enable earlier intervention (e.g., first-line consolidation in B-cell lymphomas) and serve patients who lack access to specialized manufacturing centers or cannot tolerate cytotoxic lymphodepleting chemotherapy 11.

2. Pipeline Landscape

Table 1: In Vivo CAR-T Pipeline Overview (2026–2029)

Abbreviations: FIH = first-in-human; IND = Investigational New Drug application (FDA); CTA = Clinical Trial Authorization (EMA); PoC = proof-of-concept; BCMA = B-cell maturation antigen; R/R = relapsed/refractory; MG = myasthenia gravis; CRISPR = clustered regularly interspaced short palindromic repeats 1011

3. Deal and Financing Landscape

The in vivo CAR-T deal environment has been defined by large-scale acquisitions and milestone-rich partnerships, with aggregate deal value exceeding US$15 billion since 2023 11.

Table 2: Selected Deal Landscape (2023–2026)

Biobucks = aggregate milestone payments contingent on development and commercial success 51011

4. Regulatory and Clinical-Development Uncertainty

No FDA, EMA, or NMPA guidance specific to in vivo CAR-T has been finalized as of mid-2026. Regulatory expectations are being extrapolated from existing frameworks for ex vivo CAR-T and gene therapies 1234.

Table 3: Regulatory and Development-Risk Framework

FDA emphasizes persistence-based LTFU up to 15 years for integrating-vector products 1. EMA additionally requires integration-site analysis when clonal expansion is observed and mandates ICH S12 biodistribution characterization 4. NMPA has not issued platform-specific in vivo CAR-T guidance as of mid-2026 but historically aligns with FDA/EMA precedent; China's fast-track designation for HN2301 following NEJM publication suggests willingness to accept shorter follow-up timelines for life-threatening autoimmune diseases 11.

5. Investment Valuation Frameworks

Table 4: Investment Valuation Framework for In Vivo CAR-T Assets

Indicative valuation ranges as of mid-2026: preclinical/IND-enabling US$200M–$500M; Phase 1 (early) US$500M–$1.5B; Phase 1 (expanded safety data) US$1.5B–$3B; Phase 2 (efficacy emerging) US$3B–$7B+ 11.

Key value inflection points for 2026–2029 include: IND/CTA clearance (+15–25% valuation uplift); Phase 1 safety data (+25–50% if no major safety signals); proof-of-mechanism demonstrating CAR-T expansion and target-cell depletion (+30–60%); early efficacy signals enabling Phase 2 initiation (+50–100%); FDA Breakthrough Therapy or EMA PRIority MEdicines (PRIME) designation (+20–40%); manufacturing scalability validation (+15–30%); and partnering or acquisition events (+30–100% depending on deal terms) 11.

6. Clinical and Commercial Implications

In vivo CAR-T is most likely to enter treatment algorithms as a late-line or consolidation option before achieving broader positioning. In autoimmune diseases, it competes with repeated-dosing anti-CD20 monoclonal antibodies (e.g., rituximab), bispecific antibodies, and conventional disease-modifying antirheumatic drugs (DMARDs). Its potential value proposition is a one-time or limited-course intervention achieving drug-free remission—an outcome that chronic therapies cannot provide—but this must be demonstrated in randomized Phase 2 trials 12. In hematologic malignancies, in vivo CAR-T competes with approved ex vivo CAR-T, bispecific antibodies, and antibody-drug conjugates; it may offer a manufacturing-speed and cost-access advantage for rapidly progressive disease or under-resourced settings 11.

Critical adoption barriers include: safety monitoring requirements that may mandate inpatient observation during the first dosing cycle; payer uncertainty regarding cost-effectiveness of a therapy priced between low-cost biologics and high-cost ex vivo CAR-T; durability evidence gaps (most datasets extend less than two years); physician confidence constrained by small patient numbers; and the inherent non-reversibility of in vivo CAR-T once administered 1011. LNP-mRNA platforms may partially address reversibility concerns through transient expression, enabling redosing strategies, as demonstrated in WestGene's platform experience 10, but long-term immune reconstitution data across all platforms remain limited.

Conclusion: 2026–2029 Outlook

In vivo CAR-T has moved from preclinical concept to a multi-billion-dollar clinical investment thesis within a compressed timeframe. The 2026–2029 period will be decisive: Phase 1 safety readouts from CPTX2309, ALLO-329, KLN-1010, HN2301, and others will determine whether the favorable preliminary tolerability signals observed in WestGene's mRNA-tLNP platform translate broadly across delivery modalities and indications 51011. Regulatory clarity from FDA, EMA, and NMPA—particularly regarding long-term follow-up obligations for integrating vectors, biodistribution standards, and redosing protocols—will shape development timelines and late-stage investment decisions 1234. Manufacturing scalability, currently an unverified claim rather than demonstrated reality for most platforms, must be validated in GMP settings before the cost-of-goods advantage over ex vivo CAR-T can be realized commercially.

For clinicians: anticipate expanded clinical trial availability in SLE, myositis, B-cell lymphomas, and select solid tumors by 2027–2028, but reserve judgment on efficacy and durability until randomized Phase 2 data are available. For biotech strategists and healthcare investors: monitor Phase 1 data readouts, regulatory designation announcements, and partnering events as the primary value inflection signals through 2029, and apply rigorous PoS-adjusted valuation discipline given the novelty of the modality and the absence of approved in vivo CAR-T precedents.